DNMT3A and chronic myelogenous leukemia, BCR-ABL1 positive: As expected, CML/CEL-mediated demethylation was abrogated by the dCAS9-DNMT3a-mediated methylation, and the increased fold change of the average DNA methylation rate of individual CpGs between control and dCas9-DNMT3a-treated cells is about 30% (Figures 4B, C).